NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

RecruitingPhase 3

Sponsor: Epygenix

Conditions: Dravet Syndrome

Interventions: Clemizole HCl, Placebo

Countries: United States, Argentina, Brazil, Canada, Georgia, Hungary, India, Poland

This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome (DS).

Eligibility overview

Sex: ALL

Age: 2 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Key Inclusion Criteria:

1. Male and female participants 2 years and older at time of consent.
2. Participant or parent/legally authorized representative (LAR) willing and able to provide written informed consent and assent (if applicable) prior to initiation of any study related procedures.
3. Clinical diagnosis of DS. Participants must have seizures which are not completely controlled by AEDs with the following criteria:

* Onset of seizures prior to 18 months of age,
* Normal development at onset,
* History of at least one type of countable motor seizure (CMS),
* Brain MRI without cortical malformation (not including mild atrophy associated with the natural progression of DS),
* Genetic mutation of the SCN1A gene must be documented.

Key Exclusion Criteria:

1. Known sensitivity, allergy, or previous exposure to clemizole HCl.
2. Exposure to any investigational drug or device \<90 days prior to screening or plans to participate in another drug or device trial at any time during the study.
3. Seizures secondary to illicit drug (this includes concomitant use of tetrahydrocannabinol \[THC\] and nonprescription cannabidiol preparations) or alcohol use, infection, neoplasm, demyelinating disease, degenerative neurological disease, or central nervous system disease deemed progressive, metabolic illness, or progressive degenerative disease.
4. Concurrent use of lorcaserin. Note: Prior use of lorcaserin is permitted if at least 30 days have passed since the last dose.
5. Concurrent use of fenfluramine.
6. Epilepsy surgery planned during the study or epilepsy surgery within 6 months prior to Screening.

Locations (69)

Birmingham, Alabama, United States
Little Rock, Arkansas, United States
Los Angeles, California, United States
Orange, California, United States
San Francisco, California, United States
New Haven, Connecticut, United States
New Haven, Connecticut, United States
Wilmington, Delaware, United States
Kissimmee, Florida, United States
Winter Park, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Louisville, Kentucky, United States
Ann Arbor, Michigan, United States
Omaha, Nebraska, United States
Hackensack, New Jersey, United States
Marlboro, New Jersey, United States
New York, New York, United States
New York, New York, United States
Durham, North Carolina, United States
Morrisville, North Carolina, United States
Winston-Salem, North Carolina, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Philadelphia, Pennsylvania, United States
Memphis, Tennessee, United States
Austin, Texas, United States
Dallas, Texas, United States
Salt Lake City, Utah, United States
+ 39 more on CT.gov